IRIS
CRISCUOLO, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 372
NA - Nord America 289
AS - Asia 79
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
SA - Sud America 1
Totale 751
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 289
SE - Svezia 188
IT - Italia 105
RU - Federazione Russa 46
CN - Cina 45
SG - Singapore 26
FI - Finlandia 14
IE - Irlanda 9
DE - Germania 5
IN - India 4
AU - Australia 3
CM - Camerun 3
A1 - Anonimo 2
HK - Hong Kong 2
PL - Polonia 2
BR - Brasile 1
EU - Europa 1
FR - Francia 1
GB - Regno Unito 1
KR - Corea 1
PH - Filippine 1
RO - Romania 1
ZA - Sudafrica 1
Totale 751
Salva come PNG Salva come JPEG
Città #
Ashburn 75
Milan 65
Princeton 39
Lawrence 38
Shanghai 37
New York 26
Moscow 19
Helsinki 13
Singapore 11
Dublin 9
Rome 7
Boardman 5
Ancona 4
Pune 4
South San Francisco 4
Turin 4
Washington 4
Bologna 3
Busto Arsizio 3
Council Bluffs 3
Los Angeles 3
Magnago 3
Melbourne 3
Bergamo 2
Como 2
Gatchina 2
Kunming 2
Kwai Chung 2
Las Vegas 2
Santa Clara 2
Seattle 2
Segrate 2
Bacoor 1
Bari 1
Beijing 1
Bloemfontein 1
Borås 1
Frankfurt am Main 1
Guangzhou 1
Houston 1
Lansing 1
Lappeenranta 1
London 1
Lübeck 1
Omsk 1
Redwood City 1
Rockville 1
San Diego 1
Shenzhen 1
St Petersburg 1
São Paulo 1
Vimodrone 1
Volgograd 1
Totale 421
Salva come PNG Salva come JPEG
Nome #
Cell-to-cell spread-blocking activity is extremely limited in the sera of HSV-1 and HSV-2 infected subjects 37
Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine 33
Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy 30
Alternative methods of vaccine delivery: An overview of edible and intradermal vaccines 28
Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19 27
Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge 26
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models 23
JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes? 23
Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. 22
Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols 22
Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro 22
Evaluation of synergistic interactions of anti-HCV/E2 monoclonal antibodies 22
A Human Stem Cell-Derived Neurosensory–Epithelial Circuitry on a Chip to Model Herpes Simplex Virus Reactivation 20
Bacteriophages and Their Immunological Applications against Infectious Threats 20
Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes 20
Broadly neutralizing human monoclonal antibodies: a novel resource against influenza viruses 20
Nanopore ReCappable sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs 20
Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects 19
Viral Respiratory Pathogens and Lung Injury 19
Circulating SARS-CoV-2 variants in Italy, October 2020–March 2021 19
The interferon landscape along the respiratory tract impacts the severity of COVID-19 19
Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects 19
The initial interplay between HIV and mucosal innate immunity 18
HUMAN MONOCLONAL ANTIBODY ENDOWED WITH ANTI-HSV-1 AND -2 ACTIVITY STRONGLY INHIBITS VIRUS REPLICATION 18
Characterization of two human monoclonal anti-E2/HCV antibodies for potential application in prevention and treatment of HCV infection 18
Interferon-β 1a inhibits SARS-CoV-2 in vitro when administered after virus infection 18
Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2 16
Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines 16
Neutralization Interfering Antibodies: a "Novel" Mechanism of Humoral Immune Mutiny and Viral Evasion? 16
Epitope mapping by epitope excision, hydrogen/deuterium exchange, and peptide-panning techniques combined with in silico analysis 16
Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials 16
Characterization of a lineage c.36 sars-cov-2 isolate with reduced susceptibility to neutralization circulating in lombardy, italy 16
Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection 16
Phage Therapy: An Alternative to Antibiotics 14
Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle 14
Role and potential therapeutic use of antibodies against herpetic infections 14
IN VIVO PROTECTION CONFERRED BY HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST HSV-1 AND 2 14
Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro 14
Smallpox vaccination-elicited antibodies cross-neutralize 2022-Monkeypox virus Clade II 13
Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides. 13
Molecular characterization of the human neutralizing response against hepatitis C virus and its role in the prediction of the infection outcome 13
Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases 12
Next Generation Vaccines for Infectious Diseases 12
Synergistic neutralization of HCV by two broadly neutralizing human monoclonal antibodies 12
IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19 11
A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells 10
Editorial: Viral escape of mucosal immunity in sexually transmitted diseases 6
Natural Flavonoid Derivatives Have Pan-Coronavirus Antiviral Activity 6
Unveiling the role of PUS7-mediated pseudouridylation in host protein interactions specific for the SARS-CoV-2 RNA genome 5
null 1
Totale 878
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.881
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.881
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012 5 0 0 0 0 0 6 0 0 0 0 1
2020/202113 2 0 0 2 4 0 2 0 0 3 0 0
2021/202284 6 3 10 10 13 7 9 2 2 9 0 13
2022/2023356 89 78 49 7 3 41 33 30 15 2 8 1
2023/2024315 1 20 42 62 19 62 9 25 13 8 18 36
2024/202555 55 0 0 0 0 0 0 0 0 0 0 0
Totale 878